Buonocore Sofia, Flamand Véronique, Goldman Michel, Braun Michel Y
Laboratory of Experimental Immunology, Universite Libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium.
Transplantation. 2003 Feb 15;75(3):407-13. doi: 10.1097/01.TP.0000044172.19087.22.
Dendritic cells (DC) at the immature state express low levels of major histocompatibility complex and costimulatory molecules and are poor stimulators of primary T-cell response in vitro. Injection of immature bone marrow-derived DC, however, was shown to prime in vivo alloreactive CD4 T lymphocytes toward type 2 cytokine-producing cells in the absence of CD8 T-cell activation.
We undertook the present study to determine whether Th2-immunization by immature DC could lead to allograft rejection. We first analyzed, in the major histocompatibility complex class II antigen-disparate B6-anti-bm12 combination, the capacity of immature DC to regulate the activity of alloreactive CD4 T cells. We then determined, in this model of weak antigenicity, whether injection of bm12 DC in B6 recipients before transplantation could modify the survival of vascularized bm12 cardiac allografts.
We confirmed that in vitro immature DC are poor stimulators of T-cell alloresponse. However, when given in vivo, immature bm12 DC primed anti-bm12 T cells for the production of interleukin (IL)-4. Moreover, they induced the acute rejection of bm12 cardiac allograft. The process of rejection was dependent on IL-4 because immunization of IL-4-deficient mice did not trigger rejection.
Allogeneic immature DC generated with granulocyte-macrophage colony-stimulating factor are potent stimulators of primary alloreactive response in vivo and prime for transplant rejection. Our results indicate that strategies based on immature DC for the induction of transplantation tolerance should be considered with caution.
未成熟状态的树突状细胞(DC)表达低水平的主要组织相容性复合体和共刺激分子,并且在体外是原发性T细胞反应的弱刺激剂。然而,注射未成熟的骨髓来源的DC已显示在体内可使同种异体反应性CD4 T淋巴细胞向产生2型细胞因子的细胞致敏,而不会激活CD8 T细胞。
我们进行了本研究以确定未成熟DC进行的Th2免疫是否会导致同种异体移植排斥反应。我们首先在主要组织相容性复合体II类抗原不相容的B6-抗bm12组合中分析了未成熟DC调节同种异体反应性CD4 T细胞活性的能力。然后,在这种弱抗原性模型中,我们确定在移植前向B6受体注射bm12 DC是否会改变血管化bm12心脏同种异体移植的存活时间。
我们证实,体外未成熟DC是T细胞同种异体反应的弱刺激剂。然而,当在体内给予时,未成熟的bm12 DC使抗bm12 T细胞产生白细胞介素(IL)-4。此外,它们诱导了bm12心脏同种异体移植的急性排斥反应。排斥过程依赖于IL-4,因为对IL-4缺陷小鼠进行免疫不会引发排斥反应。
用粒细胞-巨噬细胞集落刺激因子产生的同种异体未成熟DC是体内原发性同种异体反应的有效刺激剂,并引发移植排斥反应。我们的结果表明,基于未成熟DC诱导移植耐受的策略应谨慎考虑。